# A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

> **NCT00400478** · PHASE3 · COMPLETED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 683 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma (DLBCL)
- Follicular NHL Grade 3b

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00400478
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 683 (ACTUAL)
- **Last updated:** 2016-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00400478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00400478, "A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00400478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*